Dr. Zaidman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110Phone+1 314-362-1408Fax+1 314-362-3752
Education & Training
- Washington University/B-JH/SLCH ConsortiumFellowship, Clinical Neurophysiology, 2007 - 2008
- Washington University/B-JH/SLCH ConsortiumFellowship, Child Neurology, 2005 - 2007
- Brown UniversityResidency, Neurology, 2003 - 2004
- Brown UniversityResidency, Pediatrics, 2001 - 2003
- University of Virginia School of MedicineClass of 2001
Certifications & Licensure
- IL State Medical License 2021 - 2026
- MO State Medical License 2007 - 2025
- RI State Medical License 2003 - 2006
- American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology
- American Board of Psychiatry and Neurology Clinical Neurophysiology
- American Board of Psychiatry and Neurology Neuromuscular Medicine
Clinical Trials
- Spinraza in Adult Spinal Muscular Atrophy Start of enrollment: 2018 Aug 16
- Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA) Start of enrollment: 2018 Sep 25
Publications & Presentations
PubMed
- Child Neurology: Five-Year Update on Siblings With Riboflavin Transporter Deficiency: Stable Visual and Neurologic Status With Continued Riboflavin Therapy.Marisa A O'Brien, Susan M Culican, Marwan S Shinawi, Craig M Zaidman
Neurology. 2024-12-10 - Outcomes of early-treated infants with spinal muscular atrophy: A multicenter, retrospective cohort study.Natalie L Goedeker, Amanda Rogers, Mark Fisher, Kapil Arya, John F Brandsema
Muscle & Nerve. 2024-12-01 - 3 citationsAAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial.Jerry R Mendell, Francesco Muntoni, Craig M McDonald, Eugenio M Mercuri, Emma Ciafaloni
Nature Medicine. 2024-10-09
Journal Articles
- Safety, Tolerability, and Efficacy of Viltolarsen in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 SkippingPaula R Clemens, Vamshi K Rao, Craig M Zaidman, JAMA Neurology
- CANOMAD and Other Chronic Ataxic Neuropathies with Disialosyl Antibodies (CANDA)R Brian Sommerville, Craig M Zaidman, Glenn Lopate, Alan Pestronk, Conrad C Weihl, Robert C Bucelli, Journal of Neurology
Authored Content
- Safety, Tolerability, and Efficacy of Viltolarsen in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 SkippingMay 2020
Press Mentions
- Washington University Researchers to Present Findings at National Neurology MeetingOctober 3rd, 2019
- Duchenne Muscular Dystrophy Gene TherapyJuly 4th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: